# Vine Ventures

> Vine Ventures is Ryan Zurrer’s early-stage investment firm focused on psychedelics, mental health and adjacent wellness businesses. Its defining commitments include a pledge of 50% of general-partner carried interest to nonprofit initiatives and its role in the MAPS Regenerative Financing Vine, a revenue-sharing vehicle announced with a $70 million target in 2021.

- **Founded:** 2019
- **Founders:** Ryan Zurrer (Founder and Managing Director)
- **Products:** Early-stage venture investment, Vine Reciprocity Pledge, Regenerative Financing Vine
- **Notable:** Announced a pledge of 50% of GP carried interest to nonprofit initiatives in March 2021., Co-led TRIPP’s $11 million financing in June 2021., Helped design the $70 million-target MAPS regenerative financing vehicle announced in December 2021.

## Products & services

- **Early-stage venture investment** — Capital for companies in psychedelic medicine and adjacent mental health and wellness markets; publicly described investments include Psygen and TRIPP.
- **Vine Reciprocity Pledge** — Announced commitment of 50% of GP carried interest to nonprofit initiatives, directed by portfolio entrepreneurs and fund advisers rather than fund partners.
- **Regenerative Financing Vine** — MAPS special-purpose financing vehicle announced with a $70 million target, receiving a time-limited share of future North American MDMA revenue under the published terms; Vine said it would take no fees or carry on this vehicle.

## Achievements

- Announced a pledge of 50% of GP carried interest to nonprofit initiatives in March 2021.
- Co-led TRIPP’s $11 million financing in June 2021.
- Helped design the $70 million-target MAPS regenerative financing vehicle announced in December 2021.
- Participated in the more-than-$100 million Lykos Series A announced in January 2024; the total included conversion of previously issued notes.

## Latest updates

- **2024-01** — MAPS PBC announced its rename to Lykos Therapeutics and a Series A of more than $100 million, including note conversions; Vine was a participating investor.
- **2024-08** — Portfolio company Lykos announced an FDA complete response letter requiring an additional Phase 3 study; this was a portfolio regulatory setback, not an announcement by Vine.
- **2026-10** — Portfolio context: TRIPP’s current help materials describe mobile and XR wellness experiences and an AI companion. This is a product-status observation, not a new Vine financing announcement.

## Links

- Website: https://www.vine.vc/
- LinkedIn: https://www.linkedin.com/company/vine-ventures/
- Twitter/X: https://twitter.com/VineVentures

---

Profile page: https://yespress.io/vine-ventures
Published by YesPress — https://yespress.io
Last updated: 2026-10-27